U.S. Food Stock News

Rocket Lab (NasdaqCM:RKLB) has been selected by NASA to study a new Mars relay architecture that could support future missions to the Red Planet. The company is also in the running for NASA's Mars Telecommunications Network contract, a potential multi year role in providing deep space communications infrastructure. For investors tracking space infrastructure, this is a fresh angle on Rocket Lab beyond its launch and spacecraft services. The stock closed at $66.74, with a very large 1 year...

Investors may be wondering whether Entergy at around US$117 a share still offers value, or if most of the easy upside is already on the table. The stock last closed at US$117.44, with returns of 2.2% over 7 days, 12.1% over 30 days, 25.1% year to date and 50.3% over 1 year. These figures naturally raise questions about what is already priced in and how much risk investors are taking on at these levels. Recent coverage has focused on Entergy as a regulated utility with an established role in...

PayPal Holdings (NasdaqGS:PYPL) has launched direct Payment Links integration with Canva, allowing creators to embed global checkout and payments inside their designs. In a separate move, PayPal announced a partnership with Meta to power one tap commerce on Facebook and explore potential use of its PYUSD stablecoin in social commerce. These partnerships broaden PayPal's role in creator and social commerce payments across Canva's 265 million monthly users and Meta's social platforms. For...

Trupanion stock: recent performance snapshot Trupanion (TRUP) has drawn attention after a period of mixed share performance, with the price at $25.67 and returns showing a 1 day gain alongside weaker moves over the month and past 3 months. See our latest analysis for Trupanion. That small recent lift in the share price comes after a much tougher stretch, with the 90 day share price return at a 28.85% decline and the 1 year total shareholder return at a 31.98% loss, suggesting momentum has...

Snap (SNAP) is under fresh scrutiny after activist investors Randian Capital and Irenic Capital issued public letters pressing for changes in capital allocation, governance, AI focus, and the future of its Spectacles business. See our latest analysis for Snap. The activist letters arrive at a tense moment for shareholders, with a 90 day share price return of 39.71% and a 1 year total shareholder return of 36.78%, following a 5 year total shareholder return decline of 92.25%. If you are...

NGL Energy Partners LP announced on April 9, 2026 that its Board of Directors authorized an open-ended unit repurchase program of up to US$100,000,000 of its outstanding limited partnership interests. This sizable buyback authorization highlights management’s willingness to deploy capital toward reducing the unit count, which can meaningfully affect existing unitholders’ ownership exposure. We’ll now examine how this US$100,000,000 repurchase plan may shape NGL Energy Partners’ investment...

Corcept Therapeutics (CORT) is back in focus after the FDA issued a Complete Response Letter for relacorilant, followed by securities class action filings that question past disclosures around the drug’s approval prospects. See our latest analysis for Corcept Therapeutics. Corcept’s share price has rebounded to US$42.25, with a 30-day share price return of 25.97% and a 90-day gain of 12.67%, even though the 1-year total shareholder return is still down 37.62%. If this kind of sharp move after...

Amgen recently reported positive Phase 3 results for a subcutaneous, on-body injector version of TEPEZZA in moderate-to-severe active Thyroid Eye Disease, showing a statistically significant 77% proptosis response rate over 24 weeks versus placebo with a safety profile broadly in line with the existing IV formulation. This progress toward a more convenient delivery option could be important for patient adoption and may influence how Amgen’s thyroid eye disease franchise competes against...

In early April 2026, analysts reiterated positive views on Celsius Holdings after its acquisitions of Rockstar Energy and Alani Nu, emphasizing the company’s expanding energy drink portfolio and distribution partnership with PepsiCo. An interesting angle is how this analyst optimism persists despite concerns around integrating the new brands and questions about whether Celsius’s valuation already reflects much of its growth potential. Now we’ll explore how this continued analyst confidence...

Booz Allen Ventures, the venture arm of Booz Allen Hamilton Holding (NYSE:BAH), has invested in space technology company Portal Space Systems. The partnership focuses on rapidly maneuverable spacecraft aimed at next generation orbital operations and warfare capabilities. The move expands Booz Allen’s exposure to the space and defense sector beyond its core consulting, analytics, and cybersecurity work. For you as an investor, this indicates that NYSE:BAH is putting more focus on space as a...

Toast (TOST) just announced a partnership with Ike’s Love & Sandwiches to deploy its enterprise technology suite across 100 locations, a fresh data point for anyone tracking the company’s push with larger restaurant groups. See our latest analysis for Toast. The Ike’s rollout lands while Toast’s share price has a 90 day share price return of 28.43% decline and a year to date share price return of 22.96% decline. However, the 3 year total shareholder return of 47.66% still reflects earlier...

New York Times (NYT) is drawing fresh investor attention after outlining plans to grow digital subscriptions, broaden multimedia offerings like audio and podcasts, and sharpen digital advertising through data driven formats and new partnerships. See our latest analysis for New York Times. Those digital moves come as the share price trades at US$84.71, with a 30 day share price return of 4.83% and a 90 day share price return of 18.23%, while the 1 year total shareholder return of 77.17% and 3...

If you are wondering whether PayPay's current share price reflects its true worth, this breakdown will help you size up what you are actually paying for. After closing at US$20.36, the stock has seen a 3.6% decline over the last 7 days while still showing a 12.1% gain year to date, which can change how investors see both risk and opportunity. Recent coverage around PayPay has focused on its position in the diversified financials space and how its business profile fits into broader market...

Warren Buffett has acknowledged regret over selling part of Berkshire Hathaway's Apple stake and indicated interest in adding to the position if pricing becomes attractive again. The comments come after Buffett stepped down as CEO, offering a rare look at how Berkshire's investment thinking may evolve under the new leadership structure. Apple remains one of Berkshire Hathaway's most influential holdings, so any future move in the position could be closely watched by investors. Berkshire...

Taysha Gene Therapies recently reported that the FDA cleared it to begin the ASPIRE clinical trial of TSHA-102, its investigational gene therapy for Rett syndrome, and also granted inducement RSUs and stock options to four new employees under Nasdaq Listing Rule 5635(c)(4). This regulatory milestone for TSHA-102, coupled with preparations for potential commercialization, highlights how central Rett syndrome has become to Taysha’s business focus. Next, we’ll examine how FDA clearance to...

Wondering if Cirrus Logic at around US$154.82 is giving you fair value or asking too much for its growth story? This article breaks that question down in plain terms. The stock has shown strong recent returns, with 5.2% over 7 days, 15.6% over 30 days, 29.4% year to date, 71.6% over 1 year, 73.4% over 3 years, and 84.2% over 5 years, which naturally raises questions about how much optimism is already in the price. Recent coverage has focused on Cirrus Logic as part of wider discussions...

Aon recently expanded its digital infrastructure capabilities by appointing Stephen Fox as Managing Director and, earlier, upgraded its Radford McLagan Compensation Database with AI-specific job families and tools to better assess fast-evolving AI roles worldwide. Together, these moves show Aon deepening its role at the intersection of risk, capital, and AI-enabled workforce planning for large-scale, technology-focused clients. Now we’ll examine how Aon’s AI-focused compensation enhancements...

If you are wondering whether DoubleVerify Holdings is attractively priced or still too expensive, this breakdown will help you frame the current share price against what you might actually be paying for. The stock last closed at US$10.09, with returns of 3.2% over the past week, a 6.6% decline over the past month, and a 24.5% decline over the past year, which may have changed how the market is viewing its risk and reward trade off. Recent coverage has focused on DoubleVerify Holdings as an...

In early April 2026, Applied Materials introduced two chipmaking systems for 2nm and Angstrom-era logic chips that use atomic-level deposition to improve transistor isolation and metal gate formation for advanced AI processors. By solving key manufacturing bottlenecks in Gate-All-Around transistor structures and already seeing adoption by leading foundries, these tools deepen Applied Materials’ role at the core of next-generation AI chip production. Next, we’ll examine how this push into...

On March 16, 2026, McGill and Partners announced a collaboration with American International Group to apply agentic artificial intelligence to manage capacity deployment in the subscription market, supported by AIG’s US$1.60 billion commitment to McGill’s specialty gross premiums written portfolio, representing 25% of AIG’s capacity. This partnership highlights how AIG is tying advanced AI tools directly to underwriting decisions and capital allocation, potentially reshaping how it...

Wondering whether Vistra at around US$155.89 still offers value or if most of the opportunity is already priced in? This breakdown helps you size that up with numbers rather than hype. The stock price has moved 1.3% over the last 7 days, while the 30 day and year to date returns of a 4.7% decline and 5.7% decline sit against a 32.8% gain over the past year and a very large 3 year and 5 year return profile. Recent coverage has focused on Vistra as a major US utilities player, with attention...

In recent days, commentary around the Pacer Data & Infrastructure Real Estate ETF and Jefferies’ views on SBA Communications has highlighted American Tower’s long history of consistent dividend increases, stable long-term tower leases and comparatively strong platform quality within the infrastructure REIT space. Amid questions over competitors’ leverage, dividend cuts and potential sale processes, American Tower is being framed as a relatively dependable income and infrastructure exposure...

Vertex Pharmaceuticals (VRTX) just received U.S. FDA approval to expand the use of its cystic fibrosis drugs ALYFTREK and TRIKAFTA. This regulatory milestone widens treatment eligibility and puts the stock back in focus for many investors. See our latest analysis for Vertex Pharmaceuticals. The FDA label expansions arrive after a softer run in the share price, with a 90 day share price return of a 5.48% decline and a 1 year total shareholder return of a 7.96% decline. However, a 5 year total...

Investors may be wondering if Madrigal Pharmaceuticals at around US$519.75 a share is still offering value, or if the easy gains are already behind it. The stock has been volatile recently, with a 1.9% decline over the last week, a 20.0% return over 30 days, a 12.5% decline year to date, and a 65.6% return over the past year, alongside very large gains over 5 years. Recent headlines around Madrigal have focused on its position in the biotech space and the market's shifting expectations for...